Livzon Pharma's 3-Month Leuprorelin Acetate Microspheres 11.25mg Wins Supplementary Drug Application Approval

Stock News
09/29

Livzon Pharma (01513) has announced that its controlling subsidiary, Shanghai Livzon Pharmaceutical Co., Ltd. (Shanghai Livzon), recently received the "Drug Supplementary Application Approval Notice" (Certificate No.: 2026B06648) issued by the National Medical Products Administration, granting market approval for the leuprorelin acetate microspheres for injection 11.25mg (3-month formulation) produced by Shanghai Livzon.

The leuprorelin acetate microspheres for injection is a Class B product listed in the "National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Catalog." The indications for the 3-month formulation include: (1) premenopausal breast cancer; (2) prostate cancer; (3) central precocious puberty.

The leuprorelin acetate microspheres for injection (3-month formulation) is administered via subcutaneous injection once every 12 weeks, distinguishing it from the already marketed 3.75mg 1-month formulation. The 3-month formulation differs in formulation process, quality standards, dosage and administration, and indications. The 3-month formulation uses a completely different core excipient, poly-DL-lactide, offering the advantages of longer duration of action and fewer administrations. After injection, it maintains stable blood drug concentrations for 12 weeks, with more stable release behavior, significantly reducing the blood drug concentration fluctuations associated with repeated administration of the 1-month formulation. This alleviates patient suffering and medication burden while improving drug tolerability and accessibility.

Poly-DL-lactide is a high-molecular-weight excipient independently developed by Shanghai Livzon and serves as the core excipient controlling microsphere release. Following the successful associated review this time, the registration status of this excipient has been changed to "A." After PLGA7525, poly-DL-lactide is the company's second approved polymer, further enhancing the company's competitiveness in microsphere technology research and development.

As of the disclosure date of this announcement, the cumulative direct R&D expenses invested in leuprorelin acetate microspheres for injection (3-month formulation) amount to approximately RMB 94.0548 million.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10